by MM360 Staff | May 13, 2025 | Publications
Int J Hematol. 2025 May 13. doi: 10.1007/s12185-025-03998-y. Online ahead of print. ABSTRACT BACKGROUND: Sarcopenia, characterized by skeletal muscle loss, is increasingly recognized as a predictor of poor outcomes in hematologic malignancies. This study evaluated the...
by MM360 Staff | May 12, 2025 | Publications
Front Immunol. 2025 Apr 25;16:1565407. doi: 10.3389/fimmu.2025.1565407. eCollection 2025. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a hematological malignancy with limited treatment options for patients with relapsed/refractory MM (RRMM). Teclistamab, a B-cell...
by MM360 Staff | May 8, 2025 | Publications
Cancer. 2025 May 15;131(10):e35896. doi: 10.1002/cncr.35896. ABSTRACT BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) has curative potential and was previously considered by several experts superior to autologous stem cell transplantation (auto-SCT) for...
by MM360 Staff | Apr 17, 2025 | Publications
Int J Mol Sci. 2025 Apr 4;26(7):3369. doi: 10.3390/ijms26073369. ABSTRACT Multiple myeloma ranks as the second most common hematopoietic malignancy in terms of both incidence and mortality. Prognostic stratification is critical for optimizing therapeutic strategies,...
by | Apr 14, 2025 | Publications
Cancers (Basel). 2025 Mar 24;17(7):1081. doi: 10.3390/cancers17071081. ABSTRACT BACKGROUND/OBJECTIVES: In recent years, efforts by the scientific community to elucidate the underlying mechanisms of clonal expansion and selection within tumors have led to the theory of...
by | Apr 14, 2025 | Publications
Cancers (Basel). 2025 Apr 5;17(7):1235. doi: 10.3390/cancers17071235. ABSTRACT Background: Teclistamab (TEC) is the first B-cell maturation antigen-directed bispecific antibody approved in 2022 by the European Medicines Agency and Food and Drug Administration for...
